

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 1 084 730 A1**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
21.03.2001 Bulletin 2001/12

(51) Int Cl.7: **A61N 1/37**

(21) Application number: **00307990.2**

(22) Date of filing: **14.09.2000**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(72) Inventor: **Kroll, Mark W.**  
**Simi Valley, CA 93065 (US)**

(74) Representative: **Rees, David Christopher et al**  
**Kilburn & Strode**  
**20 Red Lion Street**  
**London WC1R 4PJ (GB)**


(30) Priority: **15.09.1999 US 396568**

(71) Applicant: **Pacesetter, Inc.**  
**Sylmar, CA 91342-9221 (US)**

**(54) Implantable cardioversion device with automatic filter control**

(57) An implantable cardioversion device includes a sensor for sensing intrinsic cardiac activity in a cardiac chamber, for example, the ventricle, and filtering the same using a bandpass filter having an adjustable center frequency. During normal sinus rhythm, the filter center frequency is set to correspond to the center frequency of normal R waves. If a sinus rhythm is not sensed, the filter center frequency is adjusted toward the frequency

characteristic of an abnormal cardiac condition, such as ventricular fibrillation. The adjustable filter may be incorporated into an automatic threshold control system so that both the filter center frequency and the threshold are varied in synchrony. The adjustable filter may also be incorporated with an automatic gain control system wherein the filter center frequency and the gain are adjusted simultaneously.



*FIG. 7*

**EP 1 084 730 A1**

**BEST AVAILABLE COPY**

## Description

[0001] This invention pertains to implantable cardioversion devices (ICDs) which sense a dangerous cardiac arrhythmia and, in response, provide therapy to the patient's heart to revert it to a normal sinus rhythm. More specifically, the present invention pertains to a device which includes a bandpass filter with a variable center frequency for detecting and categorizing intrinsic cardiac activity.

[0002] As used herein, the term "arrhythmia" refers to any abnormal heart rhythm that may be dangerous to the patient and specifically includes fibrillation, tachycardias, supraventricular tachycardias (SVT), ventricular tachycardias (VT), ventricular fibrillation and flutter (VF), and bradycardia. As further used herein, the term "therapy" refers to any means used by the ICD device to restore normal heart rhythm, such as defibrillation, cardioversion, antitachycardia pacing and drug infusion. The disclosed invention has application to ICD devices which treat tachyarrhythmias (abnormally high heart rates).

[0003] A modern conventional bradycardia pacemaker has a sensing mechanism to enable the device to inhibit pacing when the heart is beating normally. Implantable tachyarrhythmia devices must also sense the heart's intrinsic electrical activity, known as the electrocardiogram (ECG), to determine whether the patient needs treatment. ECGs exhibit highly variable amplitudes and frequencies as the cardiac activity changes from normal sinus rhythms (NSR) to other abnormal rhythms such as ventricular tachycardia and ventricular fibrillation.

[0004] U.S. Patent No. 4,184,493 to Langer et al., which issued on January 22, 1980, and is entitled "Circuit for Monitoring a Heart and for Effecting Cardioversion of a Needy Heart", describes a sensing circuit that automatically adjusts to the amplitude of the heart's electrical signal using an automatic gain control (AGC) system.

[0005] Another form of sensing system with AGC is described in U.S. Patent No. 4,903,699 to Baker et al., which issued on February 27, 1990, and is entitled "Implantable Cardiac Stimulator With Automatic Gain Control". The Baker et al. patent uses a system of comparators and adjustable thresholds to optimally detect the ECG signal.

[0006] Both of the foregoing patents describe systems which also filter the ECG signal to remove low frequency noise and artifacts. In addition, high pass filtering is used in these patents to reduce sensing of T waves during normal sinus rhythm (NSR). However, high frequency filtering also attenuates VF signals and makes it difficult to detect the same, especially since VF signals have low amplitudes as compared to signals during NSR.

[0007] Another control scheme is disclosed in commonly assigned U.S. Patent No. 5,395,393, incorporat-

ed herein by reference. This patent discloses an ICD in which a different sensing circuit is provided for sensing tachyarrhythmia (including supraventricular tachycardia), ventricular tachycardia or ventricular fibrillation, and for differentiating these conditions from normal sinus rhythm. More specifically, a sensor circuit includes an amplifier, a bandpass filter having a fixed center frequency, a dual dynamic threshold detector and a classifier for detecting tachyarrhythmia using a clustering algorithm. This type of control is commonly referred to as automatic threshold control (ATC) and while it generally works well to differentiate the various types of tachyarrhythmia from random noise, it is generally not effective in detecting tachyarrhythmia in the presence of electromyography signals (EMG) generated by muscles in the chest area, or noise due to standard 50 or 60 Hz power sources.

[0008] In view of the above mentioned disadvantages of the prior art, it is an objective of the present invention to provide an implantable cardioversion device (ICD) with an improved sensing circuit that can detect arrhythmias quickly and accurately.

[0009] A further objective is to provide an ICD which is capable of detecting dangerous cardiac conditions in the presence of extraneous signals such as noise from standard power supplies or muscular activity.

[0010] Yet a further objective is to provide a system which can be implemented easily with minimal changes to existing sensing circuits.

[0011] Other objectives and advantages of the invention shall become apparent from the following description.

[0012] Briefly, an implantable cardiac stimulator constructed in accordance with this invention includes a sensor for sensing intrinsic cardiac activity in the heart of a patient and a detector for detecting an abnormal condition of the heart based on this sensed intrinsic activity. The stimulator further includes a therapy generator for automatically applying a preselected therapy when the abnormal condition is detected to cause the heart to revert quickly and reliably to a normal sinus rhythm. Preferably the sensor includes an amplifier for amplifying the signals from the heart and a filter for filtering the signals prior to providing the same to the detector. Importantly, the filter has a programmable or adjustable center frequency  $f_c$ . A controller is also provided to control the center frequency  $f_c$  of the filter.

[0013] It has been found that intrinsic signals sensed during normal sinus rhythm and during ventricular fibrillation have different characteristic frequency spectra. More specifically, the spectrum for normal sinus rhythm has a center frequency which is higher than the center frequency of the spectrum characterizing ventricular fibrillation (Vf).

[0014] Therefore, during a normal sinus rhythm period, the center frequency of the filter in embodiments of the present invention is set to correspond to the center frequency ( $f_{nsr}$ ) of sinus rhythm R waves. If ventricular

fibrillation is suspected, for example, because R waves characteristic of a normal sinus rhythm are not detected, the center frequency  $f_c$  is changed to  $f_vf$ . Thus, the filter is tuned automatically so that it is optimized to detect ventricular fibrillation waves while rejecting or at least de-emphasizing extraneous noise signals produced, for example, by muscle contractions in the chest area and/or noise from external 50 or 60 Hz power supplies. After the heart chamber reverts to normal sinus rhythm, the center frequency of the filter is returned to its original value.

[0015] In this manner, the condition of the patient's heart is quickly determined and therefore appropriate therapy can be applied effectively.

[0016] Preferably, the center frequency  $f_c$  is changed gradually from one value to the other.

[0017] In one embodiment of the invention, an automatic threshold control (ATC) scheme is used. In this embodiment, the filtered output is fed to a comparator for comparison with a threshold  $T$  which is a time varying parameter. More particularly, the threshold  $T$  is also changed at the same time that the center frequency  $f_c$  of the filter is changed. Preferably, the threshold  $T$  is decreased when  $f_c$  is decreased.

[0018] In another embodiment of the invention an automatic gain control (AGC) scheme is used. In this embodiment, the gain of the input amplifier is raised as the center frequency  $f_c$  of the filter is lowered.

[0019] The invention may be carried into practice in various ways and some embodiments will now be described by way of example with reference to the accompanying drawings, in which:-

FIG. 1A shows a somewhat stylistic ECG that is characteristic of cardiac activity with normal sinus rhythm;

FIG. 1B shows an ECG that is characteristic of ventricular fibrillation;

FIG. 1C shows a typical EMG signal;

FIG. 1D shows comparatively the intensity and spectral distribution of the various signals sensed by an ICD;

FIG. 2 shows a first prior art sensing circuit incorporating an automatic threshold control (ATC) scheme;

FIG. 3 shows graphically the operation of the system of FIG. 2;

FIG. 4 shows a second prior art sensing circuit incorporating an automatic gain control (AGC) scheme;

FIG. 5 shows graphically the operation of the system of FIG. 4;

FIG. 6 shows a block diagram of an implantable cardioversion device constructed in accordance with the present invention;

FIG. 7 shows a block diagram of a sensing system for sensing tachyarrhythmia for the device of FIG. 6;

FIG. 8A shows the threshold variation for the sensing system of FIG. 7;

FIG. 8B shows the center frequency variation for the filter in the sensing system of FIG. 7;

FIG. 8C shows graphically the operation of the sensing system of FIG. 7; and

FIG. 9 shows a block diagram for a controller for the sensing system of FIG. 7.

FIGS. 1A, 1B and 1C show various intrinsic activities that may be sensed in the ventricle. FIGS. 1B and 1C have a vertical scale which is an order of magnitude smaller than the vertical scale of FIG. 1A. The frequency spectrum and comparative amplitudes are shown in FIG. 1D.

FIG. 1A shows, in a somewhat stylized manner, sequential R waves followed by T waves characteristic of normal sinus rhythm (NSR).

FIG. 1B shows a waveform characteristic of ventricular fibrillation (VF). As seen in this figure, this waveform is very ragged and apparently chaotic.

FIG. 1C shows a waveform associated with muscle activity (EMG) in the chest area, for example, when a patient lifts his arm above his heart or lifts any weight.

FIG. 1D shows the frequency spectra for the waveforms of FIGS. 1A-1C. The center frequencies for these waveforms are indicia in the following table, together with their approximate frequencies:

Waveform Description	Center Frequency
Normal Sinus Rhythm	$f_{nsr}$ (~30 Hz)
Ventricular Fibrillation	$f_{vf}$ (~10 Hz)
Electromyogram (EMG)	$f_{emg}$ (~56 Hz)
50 Cycle AC Noise	$f_{ac1}$ (50 Hz)
60 Cycle AC Noise	$f_{ac2}$ (60 Hz)

[0020] As demonstrated by FIGS. 1A-1D, the intrinsic signals sensed during ventricular fibrillation are much smaller than those sensed during NSR and they are the same order of magnitude as the EMG signals.

[0021] Ideally, an implantable cardioversion device (ICD) quickly senses an abrupt change in the state of the patient's heart by accurately differentiating between normal sinus rhythm (NSR) and ventricular fibrillation (VF), while ignoring extraneous signals, including EMG and noise from 50 Hz or 60 Hz power supplies.

[0022] Referring now to FIG. 2, a typical prior art sensor 100 using automatic threshold control (ATC) includes an amplifier 102, a fixed center frequency band-pass filter 104, a threshold detector 106 and an R wave detector 108. As described in more detail in U.S. Patent No. 5,395,393, the signal from an electrode implanted, for example, in the ventricle is amplified by amplifier 102. After filtering, the signal is fed to a dynamic threshold detector 106. This detector compares the incoming signal to two dynamic time dependent thresholds  $T_1$  and

T2. As clearly seen in FIG. 2, both thresholds T1 and T2 initially rise after an R wave is detected, and then they both slowly decay to a lower level. The rate of decay of T1 must be slow enough to ensure that a T wave is not sensed. In the scheme of FIG. 2, when the sensed signals exceeds T1 or drops below T2, a corresponding signal High and Low is generated to R wave detector 108. The detector 108 then uses a clustering algorithm to detect the R wave and generate a corresponding  $V_s$  (ventricular sense) signal. In other known ATC schemes, a single time varying threshold level is used in conjunction with other known techniques to detect the R wave.

[0023] FIG. 3 shows an interval of NSR followed by an interval of VF and the corresponding changes in the level T1 in accordance with ATC (of the single threshold type). Once again, the amplitude of the VF signals during the ventricular fibrillation interval has been emphasized for the sake of clarity. As it can be seen from this figure, after the first R wave is sensed (R1), the threshold T1 gradually decreases until the second R wave (R2). When the VF interval starts, the threshold T1 decreases (i.e., the sensitivity of the system increases) since no R waves are sensed until the signals F1, F2 ... are detected.

[0024] A problem with this scheme is best appreciated from FIG. 1D which shows the spectral content and relative intensities of the NSR, VF and EMG signals, as well as noise from 50 Hz or 60 Hz power sources. These signals overlap considerably in the frequency domain, especially at frequencies higher than 25 Hz. In fact, in this frequency range, the EMG signals clearly have a higher intensity than the VF signals. Therefore, the system of FIG. 2 may incorrectly interpret power signals or power line noise since both of these have higher amplitudes than the VF signals.

[0025] FIG. 4 shows a typical, somewhat simplified, AGC control scheme. In this figure a sensor system 150 consists of an amplifier 152 having a variable gain G. The output of the amplifier 152 is fed to a fixed center frequency bandpass filter 154 and then to a comparator 156. This comparator 156 compares the output of amplifier 152 to a predetermined threshold T0. The output of comparator 156 is fed to an R wave detector 158 which uses a further time-related criteria (such as blanking periods) to detect R waves and generate a corresponding  $V_s$  signal. The  $V_s$  signal is also fed to a controller 160 which generates a time varying gain G. This gain slowly increases with time and is slowly decreased after an R wave is sensed.

[0026] The operation of the system 150 is shown in FIG. 5. The waves R1 and R2 are sensed in the normal manner. During the VF period, the gain G increases gradually thereby boosting the peak amplitudes of the VF signals such as F1, F2, F3... until they are detected. This system has the same deficiencies as the ATC system shown in FIGS. 2 and 3 and can additionally suffer from control loop instabilities.

[0027] FIG. 6 shows a block diagram for an implantable cardioversion device (ICD) in accordance with the present invention, which, in this case, is incorporated into a dual chamber pacemaker 10 and will be described as a subsystem thereof. However, it should be understood that the ICD need not be part of a pacemaker. Nor must the system include pacing in both chambers. In the illustrated embodiment, pacemaker 10 includes an analog section 12 and a digital section 14 incorporated in an hermetic implantable housing 16. The analog section 12 includes an atrial sensor 20, an atrial pacer 22, a ventricular sensor 24, a ventricular pacer 26 and a defibrillation pulse generator 28.

[0028] Leads 32 and 34 connect the pacemaker 10 to the atrial and ventricular chambers of the heart 36, respectively. The atrial and ventricular sensors 20, 24 are used to sense intrinsic events in the corresponding cardiac chambers (i.e., signals originating in the patient's heart), and the atrial and ventricular pacers 22, 24 provide respective atrial and ventricular pacing via leads 32 and 34, for example, in a DDD or DDDR mode, well known in the art. Cardioversion, for example by antitachycardia pacing (ATP) pulses, may be generated by atrial and ventricular pacers 22, 26 in response to a therapy generator (preferably within the digital section 14) configured to deliver a prescribed therapy regime. If ATP fails, the therapy generator will cause the pulse generator 28 to deliver defibrillation shocks via lead 38. Energy for the pacemaker 10 is provided by a power supply 90. A separate high voltage supply 92 is used to feed the defibrillator pulse generator 28.

[0029] The operation of the pacemaker 10 is controlled by the digital section which preferably consists of a microprocessor 40 and a memory 42. The memory 42 holds programming information for the microprocessor 40 and is also used for data logging. Initial programming, as well as any programming updates and subsequent downloading of logged data, take place through a telemetry circuit 44. An internal bus 46 couples the memory 42, microprocessor 40 and telemetry circuit 44 together and to a digital section interface 48. Similarly, the various elements of the analog section 12 described above are connected to an analog section interface 50 by an internal bus 52. Communication between sections 12 and 14 is established through a bus 54.

[0030] Importantly, ventricular sensor 24 includes, as shown in FIG. 7, an amplifier 72, a variable bandpass filter 74 and a comparator 76. The sensor 24 also includes a control circuit 78 and a detector 80. It should be understood that some of the elements shown as discrete circuits in FIG. 7 may actually be implemented by software in the digital section 14. The intrinsic signals sensed in the ventricle are fed to amplifier 72. This amplifier 72 may have a variable gain G, if desired, as set forth above. However, in this embodiment, it is assumed that its gain is constant. The output of amplifier 72 is fed to variable bandpass filter 74. This filter has a variable center frequency  $f_c$  controlled by control circuit 78. Dur-

ing NSR, the center frequency of the filter 74 is set to  $f_{nsr}$ , i.e., the frequency of the R waves sensed during normal sinus rhythm. This frequency  $f_{nsr}$  is dependent on a number of different criteria, including the characteristics of the electrodes, their position within the ventricle and so forth. In FIG. 1D,  $f_{nsr}$  is shown at about 30 Hz.

[0031] The output of the filter 74 is fed to a signal processor portion comprised of a comparator 76 and a detector 80. The comparator 76 compares the received signal to a time varying threshold T. The output of the comparator 76 is fed to detector 80 which analyzes the output of the comparator and generates a signal  $V_s$  indicative of an intrinsic ventricular contraction. This determination may be made in a number of different ways which are known in the art and which do not limit the present invention.

[0032] Importantly, the signal  $V_s$  is also fed to control circuit 78. The control circuit 78 monitors the generation of the signal  $V_s$  and, in response, controls the center frequency  $f_c$  of filter 74. Optionally, the control circuit 78 also generates a variable gain G for amplifier 72, as discussed in more detail below.

[0033] As shown in detail in FIG. 9, the control circuit 78 includes a timer 84 which is triggered by R waves sensed by detector 80. As indicated by sawtooth shaped waveform A, each time an R wave is sensed, the timer starts waveform A at its maximum amplitude. The signal represented by waveform A is then fed to multipliers 86 and 88. These multipliers multiply this signal by appropriate scaling constants to generate respectively the threshold T and the center frequency  $f_c$ . Therefore, these parameters slowly decrease from a peak value, as shown in FIGS. 8A and 8B, respectively. For instance, referring to FIG. 1D, the maximum value of  $f_c$  for detecting normal sinus rhythm is about 30 Hz ( $f_{nsr}$ ). The center frequency  $f_c$  then decays in about 1 second to about 10 Hz ( $f_{vf}$ ) for detecting VF.

[0034] The result of shifting T and  $f_c$  can be seen in FIG. 8C. Initially during an NSR period, R waves R1, R2 are detected with  $f_c$  and T being at their maximum values shown in FIGS. 8A and 8B, respectively. When VF sets in, the value of T and  $f_c$  both slowly decay. As can be clearly seen in FIG. 8C, the downward shift of  $f_c$  causes the AC noise ACN from external power supplies and EMG noise to be de-emphasized since they have a higher frequency than  $f_c$ . More specifically, as  $f_c$  gets smaller and smaller, these two noise parameters get lower and lower as shown. Meanwhile, since  $f_c$  approaches the center frequency  $f_{vf}$  characteristic of VF, the amplitude of the signals (into the comparator) gets higher and higher allowing the comparator to detect fibrillation pulses F1, F2, F3, etc. In this manner, the system is able to differentiate quickly and accurately between noise (such as ACN and EMG) and VF.

[0035] In FIG. 9, the threshold parameter T is generated as a simple sawtooth. It should be understood that a more complex waveform may be generated as well.

In addition, a double threshold scheme may also be used as taught in U.S. Patent No. 5,395,393.

[0036] In addition to changing the threshold T, the gain G of amplifier 72 (FIG. 7) may also be adjusted by control circuit 78. More specifically, as shown in FIG. 9, for this purpose the output of timer 84 (represented by waveform A) is first fed to an inverter 90. The purpose of this inverter is to invert the signal represented by waveform A to form a signal indicated by waveform B. This inversion is necessary because the gain of amplifier 72 must be raised for the detection of VF. The inverted signal (shown as waveform B) is then scaled by multiplier 92 to generate the gain signal G. While raising the amplification factor G counteracts to some extent the de-emphasis of the noise signals ACN and EMG produced by the filter 74, this effect is not very significant since the de-emphasis produced by the filter 74 is discriminatory. That is, as the center frequency  $f_c$  is shifted downward, the amplitude of the noise components is reduced more than the linear amplification produced by raising the gain G.

[0037] After defibrillation therapy is applied, the cardiac chamber usually reverts to normal sinus rhythm. This event is detected by detector 80. In response, the control circuit reverses the process(es) described above and returns the center frequency  $f_c$ , threshold T and/or gain G to their original (i.e., normal sinus rhythm values).

## Claims

1. An implantable cardiac stimulator (10) configured to detect the presence of a normal sinus rhythm or an abnormal cardiac condition of a patient's heart (36) in response to a signal from a lead (34) coupled to the patient's heart (36) the stimulator comprising an amplifier (72) for receiving and amplifying a signal from the lead in the patient's heart (36), a filter (74) arranged to receive the amplified signal, a signal processor (76) arranged to process the filtered signal, and a control circuit (78), characterised in that: the filter (74) is having a filter centre frequency dynamically configurable to facilitate passing a filtered signal corresponding to a normal sinus rhythm or an abnormal cardiac condition; the signal processor (76) is arranged to generate a detected output signal corresponding to the presence of a normal sinus rhythm or an abnormal cardiac condition; and the control circuit (78) is arranged to adjust the centre frequency of the variable bandpass filter (74) in response to the detected output signal of the signal processor (76) to facilitate detection of an abnormal cardiac condition.
2. A stimulator as claimed in Claim 1, characterised in that at least one abnormal cardiac condition of the patient's heart (36) corresponds to fibrillation.

3. A stimulator as claimed in Claim 1 or Claim 2, characterised in that a normal sinus rhythm is comprised of periodic R waves and has a first centre frequency and a signal corresponding to an abnormal cardiac condition has a second centre frequency and whereby the control circuit (78) causes the filter centre frequency to adjust between the first centre frequency and the second centre frequency to facilitate detection of an abnormal cardiac condition.
4. A stimulator as claimed in Claim 3, characterised in that the control circuit (78) causes the filter centre frequency to adjust continuously between the first centre frequency and the second centre frequency following each R wave, to facilitate detection of an abnormal cardiac condition, and/or the filter centre frequency adjusts linearly between the first centre frequency and the second centre frequency following each R wave, to facilitate detection of an abnormal cardiac condition, and/or the centre frequency adjusts linearly between the first and second centre frequencies over a time period of approximately one second, following each R wave.
5. A stimulator as claimed in any preceding Claim, characterised in that the amplifier (72) is arranged to amplify the signal from the lead (34) by a gain factor and the gain factor is controllable by the control circuit (78).
6. A stimulator as claimed in Claim 5, characterised in that the gain factor is continuously controllable between a first gain factor corresponding to a normal sinus rhythm and a second gain factor corresponding to an abnormal cardiac condition.
7. A stimulator as claimed in Claim 5 or 6, characterised in that the control circuit causes the gain factor to increase in co-ordination with a decrease in the centre frequency of the variable bandpass filter (74).
8. A stimulator as claimed in any preceding Claim, characterised in that the signal processor (76) is sensitive to signals above a threshold level and the threshold level is controllable by the control circuit (78).
9. A stimulator as claimed in Claim 8, characterised in that the threshold level is continuously adjustable between a first threshold level corresponding to a normal sinus rhythm and a second threshold level corresponding to an abnormal cardiac condition.
10. A stimulator as claimed in Claim 9, characterised in that the control circuit causes the threshold level to decrease in co-ordination with a decrease in the centre frequency of the variable bandpass filter (74).
11. A stimulator as claimed in any preceding Claim, characterised in that the stimulator includes cardioverter circuitry (22,26,28) for generating therapy to revert the patient's heart (36) to a normal sinus rhythm when an abnormal cardiac condition is detected.
12. An implantable cardioversion device (10) for detecting and reverting ventricular fibrillation in a patient's heart, the device comprising a ventricular sensor (24) for sensing intrinsic ventricular activity and generating a corresponding sense signal and a therapy generator (26) for generating a prescribed therapy in response to the detector detecting ventricular fibrillation in the patient's heart, characterised in that the ventricular sensor (24) includes: a filter (74) for filtering the sense signal to generate a filtered signal, in which the filter has an adjustable centre frequency; a detector (80) for detecting ventricular fibrillation or normal sinus rhythm based on the filtered signal; and a controller (78) for adjusting the centre frequency to a value corresponding to the most recently detected normal sinus rhythm.
13. A device as claimed in Claim 12, characterised in that the detector further includes a comparator (76) for comparing the filtered signal to a threshold level.
14. A device as claimed in Claim 12, characterised in that the threshold level is time varying.
15. A device as claimed in any of Claims 12 to 14, characterised in that the threshold level has a first threshold value corresponding to a normal sinus rhythm and a second value corresponding to a ventricular fibrillation.
16. A device as claimed in any of Claims 12 to 15, characterised in that the filter centre frequency has a first filter frequency value corresponding to a normal sinus rhythm and a second filter frequency value corresponding to a ventricular fibrillation.
17. A device as claimed in Claim 16, characterised in that the controller (78) is configured to set the filter centre frequency to the first filter frequency value in the presence of a normal sinus rhythm and to adjust the filter centre frequency toward the second filter frequency value in the absence of a normal sinus rhythm.
18. A device as claimed in claim 16, characterised in that the controller (78) is configured to set the filter frequency in a range between the first and the second frequency values and for setting the threshold in a range between the first and second threshold

values.

19. A device as claimed in Claim 17 or Claim 18, characterised in that the controller (78) changes the filter centre frequency gradually from the first to the second centre frequency value, preferably linearly, and preferably over a time period of about one second. 5
20. A device as claimed in Claim 17 or Claim 18, characterised in that the controller (78) gradually and co-operatively changes the centre frequency and the threshold level. 10

15

20

25

30

35

40

45

50

55




FIG. 1A




FIG. 1B



FIG. 1C




FIG. 1D



FIG. 2  
PRIOR ART





FIG. 3

**FIG. 4**  
**PRIOR ART**






FIG. 5






FIG. 7




FIG. 8A




FIG. 8B




FIG. 9




FIG. 8C



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 00 30 7990

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
A	US 4 880 004 A (BAKER JR ROSS G ET AL) 14 November 1989 (1989-11-14) * the whole document *	1-20	A61N1/37
A	RAJA KUMAR R V ET AL: "TRACKING OF BANDPASS SIGNALS USING CENTER-FREQUENCY ADAPTIVE FILTERS" IEEE TRANSACTIONS ON ACOUSTICS, SPEECH AND SIGNAL PROCESSING,US,IEEE INC. NEW YORK, vol. 38, no. 10, 1 October 1990 (1990-10-01), pages 1710-1721, XP000161616 * the whole document *	1-20	
A	PROVAZNIK I ET AL: "ADAPTIVE RECURRENT SYSTEM FOR NOISE CANCELLATION AND ARRHYTHMIA DETECTION" PROCEEDINGS OF THE ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY,US,NEW YORK, IEEE, vol. 16, 3 November 1994 (1994-11-03), pages 1270-1271, XP000552573 ISBN: 0-7803-2051-4 * the whole document *	1-20	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			A61N
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 20 December 2000	Examiner Allen, E
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 (03/02) (PUB/2011)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 30 7990

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

20-12-2000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4880004 A	14-11-1989	CA 1325661 A	28-12-1993
		CA 1329238 A	03-05-1994
		DE 68925999 D	25-04-1996
		DE 68925999 T	10-10-1996
		EP 0350160 A	10-01-1990
		JP 2031735 A	01-02-1990
		JP 2701068 B	21-01-1998
<hr/>			

EPO FORM P0439

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82